FY2025 EPS Estimates for Bruker Decreased by Leerink Partnrs

Bruker Co. (NASDAQ:BRKR - Free Report) - Investment analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Bruker in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $2.46 per share for the year, down from their previous forecast of $2.55. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker's Q2 2026 earnings at $0.58 EPS, FY2026 earnings at $2.88 EPS and FY2027 earnings at $3.35 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The firm had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. During the same period in the previous year, the company earned $0.53 earnings per share. The company's revenue was up 11.0% compared to the same quarter last year.

BRKR has been the subject of a number of other reports. Stifel Nicolaus decreased their price target on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a report on Thursday, May 8th. Barclays decreased their target price on Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research report on Monday, February 24th. The Goldman Sachs Group cut their price target on Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Finally, Citigroup lowered their price objective on shares of Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Bruker currently has a consensus rating of "Moderate Buy" and an average target price of $60.10.

Bruker Stock Performance

Bruker stock traded down $1.89 during trading hours on Monday, reaching $36.85. 2,747,795 shares of the company were exchanged, compared to its average volume of 1,590,623. Bruker has a 12 month low of $34.10 and a 12 month high of $79.78. The firm has a market cap of $5.58 billion, a price-to-earnings ratio of 48.49, a PEG ratio of 2.16 and a beta of 1.23. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. The stock has a 50-day moving average of $40.94 and a 200 day moving average of $50.89.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date of this dividend was Monday, March 17th. Bruker's dividend payout ratio (DPR) is 38.46%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. London Co. of Virginia grew its holdings in shares of Bruker by 78.4% in the 4th quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock worth $245,820,000 after purchasing an additional 1,843,294 shares during the last quarter. Brown Advisory Inc. boosted its position in Bruker by 18.9% in the first quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company's stock valued at $100,599,000 after buying an additional 383,425 shares in the last quarter. Geode Capital Management LLC boosted its position in Bruker by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock valued at $118,081,000 after buying an additional 20,273 shares in the last quarter. FIL Ltd grew its stake in Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock worth $114,978,000 after buying an additional 1,420,102 shares during the last quarter. Finally, Sculptor Capital LP increased its holdings in shares of Bruker by 484.1% during the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock worth $100,476,000 after buying an additional 1,420,569 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.